chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe shoulder joint pain and loss of articulation of the left arm.; Severe shoulder joint pain and loss of articulation of the left arm.; This is a spontaneous report from a contactable consumer (patient).  A 67-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration administered on arm Left on 18Mar2021 09:45 (Batch/Lot Number: en6204) as 1ST DOSE, SINGLE for COVID-19 immunization.  Medical history and concomitant medications were not reported. On 25Mar2021, the patient had severe shoulder joint pain and loss of articulation of the left arm. Events were considered as serious (disability or permanent damage). Prior to vaccination, the patient was no diagnosed with COVID-19 and not tested for COVID-19 since the vaccination. The patient was recovering from the events.
Patient reported rapid heartbeat after vaccine. He also complained of dizziness, and or severe exhaustion. His blood pressure was initially 180/103 with a pulse of 85. Patient was given water and and the blood pressure was repeated, it became even more elevated 180/110 with a pulse of 83. EMT was called because patient was not improving and seemed to be deteriorating
Information has been received from a physician via in a published article, concerning a 11 year old patient with a seizure disorder and a history of mild eczema, and results of an ocular examination one year prior which were normal, who was vaccinated with a dose of VARIVAX 0.5 mL into the left deltoid without any resulted skin reaction. Concomitant therapy included daily oral Levetiracetam to treat the seizure disorder. One week following administration of the vaccine, the patient developed rhinitis and a mild fever that lasted 2 days. Two weeks following the vaccination, the patient noted blurry vision and photophobia in the right eye and her mother noted 3 whites spots on the cornea and was referred to the physician for new-onset blurry vision. On examination, visual acuity measured 20/30 OD and 20/20 OS. Corneal sensation was normal in both eyes. Intraocular pressure measured 14 mm Hg OD and 18 mm Hg OS. There was no conjunctival injection or anterior chamber inflammation. In the right cornea, there were several well circumscribed avascular opacities that appeared to be white blood cells at varying stromal depths. The left eye was unaffected. The posterior segment examination results were normal in both eyes. Epstein-Barr virus DNA was not detected by polymerase chain reaction. The patient was treated with a 1 month course of Prednisolone acetate, 1 %, starting at 4 times per day, with resolution of the interstitial keratitis at 2 weeks and return of visual acuity to 20/20. At the 6 month follow up visit, there was no sign of reoccurrence. Comment: Complications of VARIVAX have included disease caused by both wild type and Oka strain varicella zoster virus. There are few reports of ocular manifestations after varicella vacinnation in the literature, and they found no previous reports describing avascular interstitial keratitis. In the case that they had reported, the close temporal association of the vaccination and the development of a corticosteroid responsive keratitis lead them to suggest that this complication represented an immune mediated response to the vaccine strain. One possible explanation for the unilaterality is that the patient rubbed one eye with a hand that had previously touched her site of inoculation, leading to unilateral antigen presentation to the cornea and unilateral disease. Unilateral disease had frequently been described following smallpox vaccination, presumably from this type of touch. In addition, systemic disease may also manifest unilaterally. Immune medicated interstitial keratitis should be recognized as a possible adverse effect of the VARIVAX vaccine. No further information is available.
The Monovalent COVID-19 vaccine was inadvertently given to the patient who was scheduled to receive the Bivalent COVID-19 vaccination as per the recent FDA approval of the Bivalent COVID-19 vaccines. The patient was notified of the error on the same day of the incident and written communication is being drafted and sent to all patients reiterating what was discussed over the phone with the patient. Further action is underway with the guidance of the Interim Clinical Considerations for using COVID-19 Vaccines.  All patients were instructed to follow up with their primary care physician and were offered the opportunity to receive a booster dosage in line with the recommendations of the FDA.
On the morning of 2/11/2021, I woke up with SUDDEN HEARING LOSS IN MY RIGHT EAR, was dizzy, had balance issues, and was nauseous. I went to the ER. I had a CT in the ER which also was negative for stroke. My hearing loss has NOT returned, and I still have some balance issues as well for which I am receiving PT.
3/18/04-03/23/04 developed chickenpox lesions, 20 lesions started on legs and back and then scattered all over body, itchy, no fever, no meds.
developing symptoms of COVID; This is a spontaneous report from a contactable healthcare professional. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date were unknown), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The nurse asked if the patient can continue with the 2nd dose of COVID 19 vaccine after developing symptoms of COVID on an unspecified date. Outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Initial unsolicited report received from a consumer (Pfizer) (Manufacturer Report Number: 2016545037) on 08-Dec-2016. This case involves a female patient (onset age not reported) who was vaccinated with a dose of INFLUENZA VACCINE (batch number, expiration date, dose, dose in series, route and site of administration were not reported) on 20-Oct (unspecified year). Patient's medical history and concomitant medications were not reported. It was also reported patient was on lot of medication. On an unspecified date, unspecified timeframe following vaccination the patient experienced red and swollen arm along with the headache. It was reported that patient went to see the doctor on 17-Nov (unspecified year). Laboratory investigations were not reported. It was reported that she received Vaseline as a corrective treatment. The outcome of the events were not reported. List of documents held by sender: none.
Patient lost consciousness for 5 to 10 seconds, legs kicked and moved during unconscious state. Patient then came to and did not know where they were and stated was scared. Patient also appeared very pale sweating.
Numbness and tingling on whole left side of body from head to toes on side vaccine was administered. Swelling to left arm/hand.
Information has been received for the Merck Pregnancy Registry for GARDASIL from a health department nurse and from a registered nurse concerning a 15 year old female, with sulfonamide allergy, asthma, seasonal allergies and a history of smoking, who on 09-Aug-2006 was vaccinated with the first dose of GARDASIL, on 30-May-2007 was vaccinated with the second dose of GARDASIL and on 05-Dec-2008 was vaccinated with the third dose of GARDASIL (lot# 660616/0570X). Concomitant therapy included asthma medication, Meclizine, vitamins and ALLEGRA-D. The health department nurse reported that the patient was pregnant after receiving two doses of the HPV vaccine. The patient was seen at the Department on 06-Mar-2008 and a urine test was positive for pregnancy. The patient's date of last menstrual period was 30-Jan-2008. The estimated date of delivery was 05-Nov-2008, Ultrasounds were performed on 06-June-2008, 06-Aug-2008, 17-Sep-2008 and 14-Oct-2008 and results were within normal limits, small for dates, PIH and edema. A sonogram and a biophysical profile was also performed and resulted within normal limits. On 15-Oct-2008, the patient delivered a normal, healthy male baby weighing 5 pounds 3.7 ounces. There was no congenital anomalies. The baby's length was 18.5 inches and his Apgar score was 8/9 . the baby presented short foreskin. Complications during pregnancy included UTI, edema, increased blood pressure and hyperemesis. Complications during delivery included PIH and vacuum delivery. No further information is available.
A few minutes after the dose was given she walked over to me and said, "Mom, I'm going to pass out." She fainted and it kept coming in waves for about 15 minutes.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022) in a 39-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.  On 16-Feb-2022 at 7:30 PM, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 16-Feb-2022 at 7:30 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 16-Feb-2022) outcome was unknown.     For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  The patient received vaccine past its 30-day expiry date on 16-Feb-2022 at 7:30:41 PM.  Vaccine went into 2 to 8 degree Celsius thaw state on about 24-Dec-2021. The vaccine was administered up until its manufacturing expiry date of 04-Apr-2022.  Treatment information was not provided.   This case was linked to MOD-2022-542869 (Patient Link).
Last night at 1700 I was hit with extreme fatigue, this morning I was still exhausted but continued on with my day. About 5 minutes after I arrived at physical therapy, I noted swelling to my hand, clubbing to my fingers, blanching to my fingers, and my left thumb had a ganglion cyst, that was not there when I arrived at physical therapy waiting room. Over the course of about 30 minutes, as is indicated through my photo timestamped timeline my hand, and fingers had an exponential change in swelling, color, temperature, function, sensation, and pain. Similar to the symptoms experiences post operatively, I also had swelling to my right shoulder, delt, tri and bi area of which were already compromised. A key point includes a pea size node on my right hand thumps 1st pip joint, I had this post op, but also never had this before. I have a photo journal that can be shared if need be. It is easier for me to speak to someone than it is to write. there were other things experienced that would be best if verbalized.   With my 33 years of working in the ambulances, I attempted to contact my orthopedist, my primary care and finally went to my local pharmacy where I got the vaccine. I showed the pharmacy tech my hand and the previous pictures and asked her to refill a steroid script I had on file. Within an hour, I noted tremendous improvement. i will be monitoring this with the next 4 days of the steroid taper.
Severe arm soreness and lethargy, general muscle weakness and pain that began several hours after the shot but got worse approximately 28 hours post injection
Arthritis in hands, feet and ankles. (Had second Lymerix on 5/7/99)
Within 4 days after (20Nov2021) taking the Pfizer vaccine I lost my sense of smell and taste which has been going on for 2 months.; Within 4 days after (20Nov2021) taking the Pfizer vaccine I lost my sense of smell and taste which has been going on for 2 months.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 20Nov2021 (Lot number: FH8028) at the age of 59 years as dose 1, single and administered in arm right, administration date 11Dec2021 (Lot number: FH8028) as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: ANOSMIA (non-serious), AGEUSIA (non-serious) all with onset 24Nov2021 20:00, outcome "not recovered" and all described as "Within 4 days after (20Nov2021) taking the Pfizer vaccine I lost my sense of smell and taste which has been going on for 2 months.". The event "within 4 days after (20nov2021) taking the pfizer vaccine i lost my sense of smell and taste which has been going on for 2 months." and "within 4 days after (20nov2021) taking the pfizer vaccine i lost my sense of smell and taste which has been going on for 2 months." was evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anosmia, ageusia.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. No known allergies.  Follow-up attempts are completed. No further information is expected.
PT REPORTS WITHIN 48 HOURS OF RECEIVING FLUZONE QUAD (PT SPECIFICALLY REQUESTED THIS ONE AS OPPOSED TO THE FLUBLOK) TO LEFT DELTOID SHE DEVELOPED 5-7 ERYTHEMATOUS NODULES THAT ARE PRURITIC. STATES SHE SAW HER PCP WHO PRESCRIBED MUPIROCIN IN EVENT OF BACTERIAL INFECTION. DENIES FEVER, SWELLING AT INJECTION STIE, OR OTHER SYSTEMIC SYMPTOMS.
Pt had seizure approximately 30 hrs after DTaP given admitted for sepsis work-up.
Dermatitis left arm, cellulitis over are of herpetiform eruptions 4x8cm at shot site.
More frequent sciatic pain in right leg a few days after shot. Burning and twinges in right leg with new spider veins appearing. Poor circulation increased in right leg.
pt recv vax 16SEP96 & 17SEP96 c/o warmth & mild swelling @ inj site;also c/o stomach cramps, dizziness & malaise & t102-103x 24hr;18SEP96 noticed a rash on neck, face, & arms;18SEP96 sx resolved;
This spontaneous report as received from a certified medical assistant refers to a patient of unknown age and gender. Pertinent medical history, drug reactions or allergies were not reported. On an unknown date the patient was administered with an improperly stored dose of GARDASIL, 0.5 ml, intramuscular (strength, dose number, anatomical location, lot number and expiration date were unspecified). No concomitant therapies were reported. No adverse events were reported. The outcome of the events was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
Headache & NauseaVomiting Narrative: Developed symptoms of nausea and headache several hours after vaccine administration (12-22-20). Up late with symptoms of vomiting. Missed work the next day (12-23-20). Feeling much better by noon of the next day.
Vomit x1, hypoactive, hipotonico, cianotico. Treatment-IV's 17060 in 2 hours. 3:15pm Dl .4555 70cs 2hrs.
2 months ago feeling anxiety and having nightmares - night mares about falling my fear!!- not heights but falling -wakes me up every night and recently started having ice pick pains in my left side of my head and smelling odd odors while trying to sleep
This spontaneous report was received from a physician referring to a 17-year-old patient of an unknown gender. The patient's pertinent medical history, concomitant medications and drug reactions or allergies were not reported. On 09-MAR-2017, the patient was vaccinated with M-M-R II albumin status unknown (lot # M035388) (dose, route of administration, anatomical location and expiration date were not reported) for prophylaxis. It was reported that, in the period from 01-MAR-2017 to 23-MAR-2017, the M-M-R II was stored in a freezer that was not monitored twice daily for temperature variability. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1704USA000004: US-009507513-1703USA014463: US-009507513-1705USA007309: US-009507513-1705USA007310.
Administer expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine) in a 78-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine). On 09-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment product information was not provided.The vaccines were stored in freezer and they took out one to two vials and placed in fridge each day as needed.
about 24 hrs after vaccine  (12/8, evening) - chest pain (left upper chest), rather severe at times, difficulty expanding chest, some shortness of breath.  Some pain into left arm.  Subsided later that evening.  Some achiness in chest Thursday 12/9  Friday 12/10 - chest pain seemed to return, more localized to just left of sternum.  Pain with expansion of chest and some shortness of breath.
The next evening my legs especially the left side  in my knees were very soar i could hardly get up from chair felt swelled
Fever;  febrile seizure;  Negative workup at Hospital.  6/22/09 Medical records DC summary received DOS 5/20/09 - 5/22/09. Assessment: Seizure with Fever. Patient presented with twitching in right hand, progressing to upper and lower extremities bilateral. Fever. Lumbar Puncture. ICD-9 codes: 780.39
She developed pneumonia 7 days after being given the PREVNAR vaccine (13). She is the 4th of 4 cases I am submitting within 1 month of vaccination.
2 small (3 mm x 5 mm) hives appeared at injection site immediately after varicella vaccine injection.
This case was reported by a healthcare professional and described the occurrence of lymphadenopathy in a 45-year-old female subject who was vaccinated with FLUARIX (GlaxoSmithKline). The subject's medical history included allergy to SUPRAX, allergy to ZITHROMAX, environmental allergy and penicillin allergy. With the exception of the influenza virus vaccine, the subject had no adverse events following receipt of other previous immunizations. Concurrent medications included Oral contraceptives, NASACORT, XYZAL and Allergy shot. The subject received no other vaccinations on the date of receipt of FLUARIX. On an unspecified date in 2007, the subject received unspecified dose of Influenza vaccine (unknown). On an unspecified date in 2007, less than one year after vaccination with Influenza vaccine, the subject experienced lymphadenopathy. The lymphadenopathy resolved after eight days. On 28 October 2008 between 5:00 p.m. and 5:30 p.m., the subject received unspecified dose of FLUARIX (.5 ml, unknown, right arm). On the morning of 29 October 2008, 1 day after vaccination with FLUARIX, the subject experienced lymphadenopathy, erythema, lymph node palpable and lymph node tenderness. The healthcare professional considered the events that occurred on 29 October 2008 were clinically significant (or requiring intervention). The subject received treatment with steroids. At the time of reporting the events were unresolved. The healthcare professional considered the events were probably related to vaccination with FLUARIX. Nurse practitioner states subject received FLUARIX on 28 October 2008, and the following morning she developed lymphadenopathy on her neck region. Specifically, she has swollen lymph nodes above her clavicle on the right side mid-way up, and it is the diameter of a golf ball and is raised approximately 1-2 centimeters, and there is generalized erythema at this site. The swollen node is visible without palpation. Surrounding that area, there are palpable nodes that are each a centimeter in size. Below the clavicle, there are several poorly defined palpable nodes. Additionally, there are tender infraclavicular anterior nodes, axillary nodes, and tender nodes at the groove between the shoulder and chest. There is also a weblike red pattern over the neck area and upper chest. Currently, the subject is being treated with steroids. The reporter believes this is probably caused by FLUARIX since the subject experienced the same events last year after receiving the flu vaccine (Lymphadenopathy was experienced at the same location after receiving last year's flu vaccine (unknown which brand), however, it occurred a little bit later and lasted for 8 days).
Patient came in for no shots no school with mother and was given MMR and Varicella SQ in the back of the arms. Patient was advised to wait 15 minutes just to make sure patient does not have any allergic reactions. Patient went and waited in the lobby. After a few minutes later patient had a red reaction around both MMR and Varicella injection sites. Dr. advised to take over-the-counter hydrocortisone cream and CLARITIN and to go to a doctor's office or ER if it became more severe and then patient left.
Cardiac arrhythmias, multiple PVCs per minute, palpitations, and chest
Throbbing calf muscles; Splitting headache; Extreme fatigue; This is a spontaneous report from a contactable consumer (patient). A 79-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number and expiration date were not reported), via an unspecified route of administration, administered in right arm on 18Jun2021 (at the age of 79 years old) as dose 1, single for COVID-19 immunisation. Medical history included chronic lymphocytic leukaemia (CLL), osteoporosis, arthritis, and atrial fibrillation (afib). The patient is not pregnant at the time of vaccination and has not had COVID prior to vaccination. Concomitant medication included apixaban (ELIQUIS). The patient previously took sulphur and experienced Allergies to sulphur. No other vaccines in four weeks. The patient experienced throbbing calf muscles, splitting headache, and extreme fatigue on 28Jun2021, 10 days after shot. Side  effects lasted for 4 days. This was the patient's first shot. No treatment was given in response to the events. The patient was not COVID tested post vaccination. The outcome of the events was recovered on 02Jul2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.